Netanyahu denounces report that Israeli soldiers have orders to shoot at Palestinians seeking aid
JERUSALEM (AP) — Israeli Prime Minister Benjamin Netanyahu and Defense Minister Israel Katz emphatically rejected a report in the left-leaning Israeli daily Haaretz on Friday, which claimed Israeli soldiers were ordered to shoot at Palestinians approaching aid sites inside Gaza. They called the report's findings 'malicious falsehoods designed to defame' the military.
More than 500 Palestinians have been killed and hundreds more wounded while seeking food since the newly formed Gaza Humanitarian Foundation began distributing aid in the territory about a month ago, according to Gaza's Health Ministry.
Palestinian witnesses say Israeli troops have opened fire at crowds on the roads heading toward the sites. Reacting to the Haaretz piece, Israel's military confirmed that it was investigating incidents in which civilians had been harmed while approaching the sites. It rejected the article's allegations 'of deliberate fire toward civilians.'
The foundation, which is backed by an American private contractor, has been distributing food boxes at four locations, mainly in the far south of Gaza, for the past month.
'GHF is not aware of any of these incidents but these allegations are too grave to ignore and we therefore call on Israel to investigate them and transparently publish the results in a timely manner,' the group said in a social media post.
Palestinians trying to find food have frequently encountered chaos and violence on their way to and on arrival at the aid sites. Tens of thousands are desperate for food after Israel imposed a 2 1/2 month siege on Gaza, blocking all food, water and medicine from entering the territory pending the setup of the GHF sites.
The bodies of eight people who died Friday had come to Shifa Hospital from a GHF site in Netzarim, although it was not immediately clear how they died, Dr. Mohamed Abu Selmyiha, the hospital's director, told The Associated Press. A GHF spokesperson challenged the report, saying they did not know of any incidents at or near their sites Friday.
Thousands of Palestinians walk for hours to reach the hubs, moving through Israeli military zones where witnesses say Israeli troops regularly open fire with heavy barrages to control the crowds. The Israeli military says it has only fired warning shots.
Mohammad Fawzi, a displaced man from Rafah, told the AP that he was only able to get empty boxes, not food, from the aid site in the Shakoush area in Rafah when he trekked there early Thursday morning.
'We've been shot at since 6 a.m. up until 10 a.m. just to get aid and only some people were able to receive it. There are martyrs and injured people. The situation is difficult,' he said.
The group Doctors Without Borders on Friday condemned the distribution system as 'a slaughter masquerading as humanitarian aid' and called for it to be immediately shut down.
More than 6,000 people have been killed and more than 20,000 injured in Gaza since the ceasefire collapsed on March 18. Since the war began, more than 56,000 people have been killed and 132,000 injured, according to the health ministry.
The Gaza Health Ministry doesn't distinguish between civilians and combatants, but has said that women and children make up more than half the 56,000 dead. Israel says it only targets militants and blames civilian deaths on Hamas, accusing the militants of hiding among civilians, because they operate in populated areas.
The Israel-Hamas war started following the Hamas-led attack in southern Israel on Oct. 7, 2023, when some 1,200 people were killed and around 250 taken hostage. About 50 of them still remain in captivity in Gaza.
The latest deaths include six people killed and 10 wounded in Israeli strikes on a group of citizens near the Martyrs Roundabout in the Bureij Camp in central Gaza Strip, officials at Awda Hospital in Nuseirat said Friday.
The United Nations chief meanwhile urged leaders to show 'political courage' and agree to a ceasefire like the one forged between Israel and Iran.
___
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
14 hours ago
- UPI
Dozens of Palestinians killed in Israeli airstrikes in Gaza
Displaced Palestinians wait to receive aid from World Food Program USA on Thursday. Starvation is intensifying amid more Israeli airstrikes against Hamas on the Gaza Strip. Photo by Mohammed Saber/EPA-EFE June 28 (UPI) -- Dozens of Palestinians died in several rounds of Israeli airstrikes from Friday night until Saturday morning, officials said. At least 44 people died in the Gaza Strip since dawn, hospital sources told Al Jazeera Arabic. The Guardian reported at least 62 people died in overnight strikes. The Gaza Health Ministry, which is controlled by the Iran-funded militant group Hamas, said 81 people have died and 422 were wounded over 24 hours. Al Jazeera reported an airstrike in a residential building in Gaza City killed at least 20 Palestinians, including nine children. "We were sitting peacefully when we received a call from a private number telling us to evacuate the entire block immediately -- a residential area belonging to the al-Nakhalah family. As you can see, the whole block is nearly wiped out," Mahmoud al-Nakhala told Al Jazeera. "We still don't know why two, three-story homes were targeted ... It's heartbreaking that people watch what's happening in Gaza -- the suffering, the massacres -- and stay silent. At this point, we can't even comprehend what's happening here anymore," he added. Rescuers were working to remove victims from under rubble. Those hurt were taken to al-Ahli Hospital, which is lacking medical resources. There were also drone strikes elsewhere on Gaza Strip, including in the city of Khan Younis and the Bureij refugee camp. The Guardian reported that a dozen people were killed near a displacement camp near Palestine Stadium in Gaza City, after which a nearby airstrike nearby killed at least 11 people and a family sleeping in a tent was reported to have died in a strike in al-Mawasi, southern Gaza. At least 56,412 Palestinians have been killed 133,054 wounded since the war began on Oct. 7, 2023, according to Gaza's Health Ministry. Hamas' attack on Israel that day killed approximately 1,200 people and 251 hostages were taken. President Donald Trump on Friday said there could be a cease-fire agreement "within the next week" despite no signs of negotiations underway. Humanitarian conditions in Gaza have worsened since Israel resumed airstrikes on March 18 after a cease-fire that ran from Jan. 19 to March 1. Unicef said last week that 60% of water production facilities in Gaza weren't working and acute child malnutrition increased 51% from April to May. In a separate strike in southern Lebanon on Friday, Israel Defense Forces killed Hezbollah terrorist Hassan Muhammad Hammoudi, the military told the Jerusalem Post on Saturday night. Lebanon's President Joseph Aoun accused Israel of continually violating the U.S.-brokered cease-fire deal.
USA Today
14 hours ago
- USA Today
Texas politicians lead effort to study a psychedelic drug. What is ibogaine?
Ibogaine is illegal in the U.S., but growing evidence shows its promise treating the effects of traumatic brain injury and substance use disorder. A once obscure traditional psychedelic plant from Africa has made headlines recently as Texas pushes for more research and a prominent Republican wrote a vigorous endorsement of its possible use for the treatment of addiction and for veterans experiencing mental health issues. Ibogaine is illegal for use in the United States, but a growing body of evidence has shown its promise treating the effects of traumatic brain injury and substance use disorder. Earlier in June, Texas Gov. Greg Abbott signed legislation to allocate $50 million for clinical trials approved by the Food and Drug Administration to study ibogaine. Texas is set to lead research into the drug's benefits treating mental health issues and addiction as a potential medication. Former Energy Secretary Rick Perry, also a former Texas governor, wrote a June 27 Washington Post op-ed supporting ibogaine research and criticizing the legacy of the war on drugs, started by President Richard Nixon and touted by President Ronald Reagan. Perry said he has 'come to realize just how wrong that narrative was.' 'That fear-based messaging kept us from exploring treatments that could have saved countless lives,' Perry wrote. Perry and a growing number of conservatives have argued ibogaine could be one of those treatments. Here's what to know about the drug. What is ibogaine? Ibogaine derives from the root of the iboga plant native to western-central Africa. It's been used in ceremonial rituals for centuries. It has hallucinogenic properties. The United States outlawed ibogaine in 1967 along with other psychotropic drugs. The Controlled Substances Act of 1970 placed it as a schedule I hallucinogenic drug, along with marijuana. Ibogaine's classification prevented researchers from studying its effects. But unlike other schedule 1 drugs such as heroin, ibogaine has anti-addictive properties. There are risks since ibogaine can delay the body's normal electrical signals that control heart rhythm, which could lead to death. Other countries, such as Mexico, have allowed its use. American veterans and others have traveled to smaller, clandestine clinics for treatment to deal with depression, post-traumatic stress disorder and addiction. Many clinics are along the border and around cities such as Tijuana. Why is it in the news? At the state and federal level, there is growing interest in studying psychedelic drugs to treat veterans and others. Texas passed legislation earlier in June to study the drug with a public university alongside a company and hospital, Abbott's office said. Dr. Marty Makary, the FDA commissioner, has said expanding research on psychedelic drugs is a top priority for the Trump administration. In his op-ed, Perry cited the experiences of Morgan and Marcus Luttrell, twin combat veterans, who used ibogaine for recovery. Morgan Luttrell is now a Republican congressman from Texas who has advocated for ibogaine and other psychedelic drugs as treatment options. In January 2025, Perry and W. Bryan Hubbard, an advocate for ibogaine treatment, appeared on Joe Rogan's podcast to discuss ibogaine's benefits as a plant-based medicine. Hubbard led a Kentucky task force that sought to use opioid settlement funds to research ibogaine's effects to treat addiction, but the initiative failed to gain support in the state. Hubbard and Perry eventually launched the Texas Ibogaine Initiative, which helped spur the state funding. What has research shown? Research, such as a Stanford University study of 30 male combat veterans, has shown ibogaine's promise. Coupled with magnesium sulfate to address heart effects, ibogaine appeared to reduce symptoms of PTSD, anxiety and depression, and improve cognitive function from traumatic brain injury, according to the study, published in 2024 in the eminent journal Nature Medicine. Other studies have shown benefits treating addiction and depression. What do critics say? One issue with ibogaine is the ability to produce it, because it is derived from a rare plant and has mostly been used for ceremonial purposes. There is research to help innovate its safe production, but it could be difficult for the drug to be more widely available, as researchers at the University of California, Davis, Institute for Psychedelics and Neurotherapeutics have said. And while it's shown benefits with combat veterans, questions remain on its efficacy among randomized participants. With Texas' research, ibogaine could get closer to FDA approval for its use as a medication.
Newsweek
15 hours ago
- Newsweek
This New Test Could Diagnose Parkinson's With AI
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A new artificial intelligence (AI) tool analyzing short smile videos achieved high accuracy in screening for Parkinson's disease (PD), according to research published by Tariq Adnan, and colleagues in the New England Journal of Medicine (NEJM) Thursday. The model was trained on the largest known video dataset of facial expressions to date, enrolling 1,452 participants, including 391 living with PD. An 87.9 percent overall accuracy in detecting PD using only smile video analysis, the NEJM AI study reported. Researchers reported that the AI model could accurately distinguish between individuals with and without PD based on the analysis of their smiles, even when applied in diverse population samples from North America and Bangladesh. Why It Matters The Parkinson's Foundation says an estimated 90,000 more people will be diagnosed this year, with the number of those suffering expected to be around 1.2 million by 2030. Diagnosing Parkinson's disease early remains a significant challenge because of limited access to clinical expertise and in-person evaluations. AI-driven remote screening tools promise scalable, cost-effective solutions to bridge these healthcare gaps. The findings align with the growing demand for digital healthcare solutions that remove geographical and economic barriers to early neurological disease diagnosis, which is especially relevant to rural and underserved American communities. What To Know The new screening method invited participants to record themselves mimicking facial expressions—including a smile—using an online platform. Research teams then extracted facial landmarks and measured action units to quantify hypomimia, a common motor symptom in PD where facial muscle movement is diminished. Machine learning models were developed using these features, distinguishing people with PD from those without. The approach relied on a broad recruitment strategy, involving participants from North America via social media, email, wellness centers, and research registries, alongside a high-risk cohort from Bangladesh. Trained solely on smile videos, the model achieved a 10-fold cross-validated accuracy of 87.9 percent, a sensitivity of 76.8 percent, and a specificity of 91.4 percent. Validation in external test sets revealed 80.3 percent accuracy in a U.S. clinic dataset and 85.3 percent accuracy in the Bangladesh cohort. While the negative predictive value remained above 92 percent in all settings, the positive predictive value dropped to 35.7 percent among the Bangladeshi participants, reflecting variations in population characteristics. The study found no significant differences in model performance across sex and ethnic subgroups, except for marginally higher accuracy in female participants in Bangladesh. The authors emphasized the generalizability and fairness of the approach, key considerations in the development of clinical AI tools. The video-processing and machine-learning code supporting the study is available to the public on GitHub. However, the study authors noted that raw video data sharing is restricted to comply with U.S. healthcare privacy law (HIPAA), limiting access to de-identified derivative features only. The research received funding from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, among other sources. The work was a collaborative effort involving academic and clinical partners such as the InMotion Parkinson's Disease wellness center and the University of Rochester Center for Health and Technology. The research process also benefited from contributions by staff at Google Research and the University of Rochester, particularly in statistical analysis. Stock image of brain MRI taken November 21, 2018. Stock image of brain MRI taken November 21, 2018. Getty What People Are Saying Tariq Adnan, lead author said in the study conclusion: "Smiling videos can effectively differentiate between individuals with and without PD, offering a potentially easy, accessible, and cost-efficient way to screen for PD, especially when access to clinical diagnosis is limited." What Happens Next? Future steps for the research team involve wider validation of the AI screening method in additional, real-world populations and further refinement of the algorithm to maximize early detection accuracy. Regulatory and clinical translation pathways will determine if and when this technology becomes available in the United States healthcare system.
